The 10 drugs that CMS might wrangle into negotiations

CMS plans to soon release its list of 10 drugs that are up for price negotiations as it gears up to wield new powers granted by the Inflation Reduction Act, which passed in August 2022.

Researchers from the Washington, D.C.-based West Health Policy Center and the University of California San Diego studied which drugs might be chosen by CMS. They evaluated drug age — since only those older than a decade are eligible — Part B and Part D gross spending in 2020, and estimates of when a drug will lose its exclusivity status.